Our findings may provide a preliminary basis for the use of a 15 mCi dose of radioiodine upon rhTSH stimulation in thyroidectomized patients with Graves' hyperthyroidism and GO.
Introduction
Graves' orbitopathy (GO) is usually associated with Graves' hyperthyroidism (GH) and less frequently with autoimmune thyroiditis or subclinical thyroid autoimmunity [1] [2] [3] , suggesting a link between the thyroid and orbital tissues [4, 5] . Thus, GO probably reflects autoimmunity against antigens present in both tissues [5] . Treatment options for GO include glucocorticoids, radiotherapy, and various surgical procedures [6, 7] , as well as monoclonal antibodies against CD20 or the insulin-like growth factor receptor, the former two still in the experimental phase [8] [9] [10] .
Based on the hypothesis that GO is due to autoimmunity against antigens common to the thyroid and the orbit, it has been proposed that elimination of thyroid antigens, namely, total thyroid ablation (TTA), may be beneficial for GO [6] . Nowadays, TTA is performed with a radioiodine dose of 30 mCi, administered after recombinant human TSH (rhTSH) [11, 12] . According to the Italian legislation, this dose of radioiodine must be followed by a 24-h protected hospitalization, which, limited to Italy, implies an increase of the waiting list, due to the low number of protected beds and, concerning GO, to the competition with patients with thyroid cancer. Still in Italy, a radioiodine dose of 15 mCi can be given to outpatients without hospitalization and with lower costs. Considering that GH and, therefore, GO patients
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usually have serum stimulating TSH-receptor antibodies (TRAb) that persist after thyroidectomy and may increase radioiodine uptake [13] [14] [15] [16] , we considered the possibility that they may need a lower dose of radioiodine to ablate thyroid remnants, which we investigated here in a perspective study.
Subjects and methods
The study was performed in two groups of thyroidectomized patients with GH and GO who had a differentiated thyroid cancer at histology, with a low-risk according to the American Thyroid Association guidelines [12] . Within 3 months from thyroidectomy, patients underwent 131 I ablation. Ablation was performed mainly for moderately severe GO, rather than for thyroid cancer, although the treatment could be considered to some extent useful, although likely obsolete, also for the former. The first 12 consecutive patients undergoing ablation with either 15 or 30 mCi of 131 I were included. Patients were not selected, but consecutive, although they were not randomized. Therefore, the study should be considered as observational. The sample size was the minimum required for a statistical analysis to be performed, as, to our knowledge, no previous data were available. In the 15 mCi group, the radioiodine dose was given arbitrarily to shorten the waiting time, because of a concomitant, severe GO that required prompt treatment.
The primary outcome was rhTSH-stimulated serum thyroglobulin (Tg) at 6 months. The secondary outcome was baseline Tg at 6 months. In addition, the outcome of GO in the two groups was evaluated.
The study was registered at ClinicalTrials.gov (registration number: NCT03110835) and performed in accordance with Institutional guidelines. Being an observational study, approval by the local Review Board was not required.
Inclusion criteria were: (1) a diagnosis of GH before thyroidectomy, based on FT4 ≥ 17 pg/ml and/or FT3 ≥ 5.7 pg/ ml, low TSH (≤0.4 mU/l), and detectable TRAb [8, 9] ; (2) near-total thyroidectomy; (3) undetectable anti-Tg autoantibodies (TgAb); (4) informed consent; and (5) absence of exclusion criteria, namely: (1) previous radioiodine treatment; (2) detectable TgAb; and (3) lack of informed consent. Patients could exit from the study at any time, or under the following circumstances: (1) any event that prompted a change in the treatment schedule and (2) lack of compliance to treatment and assessments.
Twelve consecutive patients who met the inclusion criteria were included (4 men, 8 women; age 50.5 ± 13 year, range 25-71 years). A single dose of 0.9 mg rhTSH was administered intramuscularly 48 and 24 h before radioiodine. All patients were on LT4 therapy at replacement doses. None of the patients had been treated with glucocorticoids before radioiodine. Between the ablation and the 6 month evaluation, all patients were treated with intravenous glucocorticoids (ivGC). Patients were given one iv infusion/week of methylprednisolone for a total of 12 infusions. The dose was 500 mg for the first six infusions and 250 mg for the last six infusions, for a cumulative dose of 4.5 g, as described previously [7] . No major side effects of GC were observed. Orbital radiotherapy was performed in one patient per group, and it was started concomitantly with ivGC. A high-voltage linear accelerator was used and a cumulative radiation dose of 20 Gy was delivered to each eye in ten fractionated doses over a period of 2 weeks. All patients were treated in both eyes.
All patients underwent the following assessments and measurements at ablation and then at 6 months: (1) physical evaluation; (2) 24-h 131 I uptake (only at baseline); (3) thyroid scan 72 h after radioiodine; and (4) serum assays: FT 4 and FT 3 (Vitros Immunodiagnostics, Raritan, NJ); TSH (Immulite 2000, Siemens Healthcare, Gwynedd, UK); TRAb (RSR Ltd Cardiff, UK); TgAb (AIA-Pack TgAb, Tosoh Bioscience, San Francisco, CA); and Tg (Beckman Coulter, Fullerton, CA). At 6 months, patients underwent a Tg-stimulation test, namely, 0.9 mg rhTSH intramuscularly for 2 consecutive days, with daily measurements of Tg up to 5 days.
All patients underwent an ophthalmological assessment at ablation and then at 6 months, which included: (1) exophthalmometry; (2) measurement of eyelid aperture; (3) evaluation of the Clinical Activity Score (CAS) according to Mourits (13) ; (4) assessment of diplopia; (5) assessment of the corneal status; (6) examination of the fundi; and (7) measurement of visual acuity. The overall GO outcome was evaluated, as described in [14] . Briefly, GO was considered improved when at least two of the following criteria were fulfilled, without worsening of the other criteria: (1) reduction in proptosis ≥2 mm in at least one eye, with no increase ≥2 mm in the other eye; (2) reduction of CAS ≥ 2/7 points; (3) reduction in eyelid aperture ≥2 mm in at least one eye, with no increase ≥2 mm in the other eye; (4) disappearance or improvement (change of degree from constant to inconstant or intermittent, or from inconstant to intermittent) of diplopia; and (5) increase in visual acuity ≥2/10. GO was considered worsened when at least two of the following criteria were fulfilled: (1) increase of CAS ≥ 2/7 points; (2) increase in proptosis ≥2 mm; (3) increase in eyelid aperture ≥2 mm; (4) appearance or worsening (change of degree) of diplopia; and (5) decrease in visual acuity ≥2/10. In all other instances, GO was considered stable.
Numerical data are presented as median and IQR. The following statistical tests were performed, as appropriate: (1) Chi square; (2) Mann-Whitney; and (3) paired sign.
Results
Demographic features, serum assays, and radioiodine uptake at ablation are illustrated in Table 1 . All patients completed the study. The two groups did not differ for age and gender. At ablation, serum FT 3 , FT 4 , TSH, and TSH after rhTSH, and TRAb, Tg, and Tg after rhTSH did not differ between the two groups. A thyroid scan 72 h after ablation showed a thyroid remnant in all cases. At 6 months, the two groups were similar concerning FT 3 , FT 4 , TSH, TSH after rhTSH and TRAb. Baseline Tg and Tg after rhTSH at 6 months did not differ between two groups, suggesting a similar extent of ablation. At 6 months, rhTSH-stimulated Tg was reduced significantly compared with rhTSH-stimulated Tg at ablation in both groups (P = 0.03 by paired sign).
GO features of the two groups are illustrated in Table 2 . Patients in both groups had a moderately severe, active GO. All patients were treated with ivGC and one patient per group underwent orbital radiotherapy between ablation and the 6 month evaluation. GO improved in 50% and remained stable in the remaining 50% of patients in both groups, with no statistical difference between the two groups. The findings is in line with similar observations in patients treated with total thyroid ablation followed by ivGC at 6 months (3 months after the end of ivGC) [14] . Individual GO features at ablation and then at 6 months were not significantly different within groups, presumably because of the limited number of subjects. There was no difference between the two groups for each parameter both at ablation and at 6 months.
Discussion
Our findings may provide a basis for the use of a 15 mCi dose of radioiodine upon rhTSH stimulation in thyroidectomized patients with GH and GO. Thus, a 15 mCi dose was as effective as a 30 mCi dose in causing ablation, as measured by baseline and rhTSH-stimulated Tg at 6 months, which both did not differ between the two groups. Patients had stimulating TRAb that very likely increased radioiodine uptake, which probably explains the findings. In theory, the presence of stimulating TRAb may be sufficient for ablation even in the absence of rhTSH, although because the level and bioactivity of TRAb may vary between individuals, it would be difficult to perform ablation without rhTSH on a regular basis. It may be argued that a late thyroid scan could have been informative on the extent of ablation and further studies are needed to investigate whether a low dose of radioiodine is effective also under this point of view.
Tg at ablation (both baseline and after rhTSH) was apparently lower in the 15 mCi group, but the difference with the 30 mCi group was not statistically significant. We do not have an explanation for this apparent difference, which was likely casual and of poor relevance, considering that patients were not selected, even though not randomized, but recruited consecutively among GO patients undergoing ablation with 30 or 15 mCi. Ablation for GO was originally proposed by Catz and Perzik [17] . Two retrospective studies showed an improvement of GO following TTA [18, 19] . A randomized clinical trial was performed in patients with moderately severe GO treated with intravenous glucocorticoids (ivGC), either after thyroidectomy or TTA, namely, thyroidectomy followed by 30 mCi of radioiodine given in hypothyroidism after LT4 withdrawal [14] . The short-term outcome of GO (at 3 and 9 months) was more favorable in the TTA group [14] . In a continuation of the same study, the long-term (~90 months) GO outcome was similar in the two groups, but the time required for GO improvement was shorter after TTA [20] . In another randomized study in which ablation was performed with rhTSH, the better outcome of GO after ivGC in patients who underwent TTA was confirmed [21] . In the present, small cohort, GO improved in 50% of patients regardless of the radioiodine dose, a percentage that is in keeping with previous observations in patients treated with TTA and ivGC, and which was shown to be greater than that observed in patients treated with thyroidectomy alone and ivGC [14] . However, although confirmatory, the present findings do not add much in defining the usefulness of ablation in GO patients treated with ivGC, as there were no direct comparisons with patients treated with ivGC, but not with TTA.
In spite of these findings, TTA is not among the treatment modalities for hyperthyroidism suggested by the European Group On Graves' Orbitopathy (EUGOGO) guidelines [7] , presumably because of the limited number of studies and on the fact that the effectiveness of TTA was demonstrated only in patients with moderately severe GO given ivGC, and compared only with thyroidectomy, but not with anti-thyroid drugs or radioiodine alone. Possibly, the present observation that a lower dose of radioiodine may be used for ablation will make further studies easier to perform and will clarify whether TTA should be used on a regular basis. Thus, at least in Italy, the finding that 15 mCi of radioiodine are as effective as 30 mCi may provide the possibility of ablating a greater number of patients, with a remarkable reduction of the waiting time and of the social costs. Clearly, this is less important in countries other than Italy that allow the administration of greater doses of radioiodine to outpatients.
An obvious limitation of the present study is the small number of patients and our data await confirmation in larger cohorts. Thus, our findings should be considered preliminary. In addition, it remains to be investigated whether the low-dose radioiodine ablation results in a better GO outcome, which will also be the subject of future studies. Taking into account the limitations due to the small number of patients, we did not find any difference in terms of GO outcome following a similar treatment procedure (ivGC) for the eye disease between patients given 15 or with 30 mCi of radioiodine, which supports further the possibility of using 15 mCi of radioiodine to ablate GO patients.
It may be argued that radioiodine treatment may determine immune stimulation, because of the release of thyroid autoantigens. Laurberg et al. showed a short-time increase in TRAb in GH patients treated with radioiodine, peaking at ~6 months, followed by a slow reduction, in contrast with patients treated with thyroidectomy, in whom there was a rapid reduction of TRAb [22] . In that study, patients given radioiodine had not undergone a previous surgery and were not given steroids, which probably explains the increase in TRAb. Unlike in the study from Laurberg et al. [22] , patients in the present study had only thyroid remnants, having been already subjected to thyroidectomy, and in addition, they were treated with ivGC. Thus, it is not surprising that in our patients, TRAb levels did not increase after radioiodine, which is quite reassuring in terms of stimulation of the immune system in patients with GH and GO.
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